Robbins Gregory R, Roberts Reid A, Guo Haitao, Reuter Kevin, Shen Tammy, Sempowski Gregory D, McKinnon Karen P, Su Lishan, DeSimone Joseph M, Ting Jenny P-Y
Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Nanomedicine. 2015 Apr;11(3):589-99. doi: 10.1016/j.nano.2014.11.010. Epub 2015 Jan 14.
Ideal nanoparticle (NP)-based drug and vaccine delivery vectors should be free of inherent cytotoxic or immunostimulatory properties. Therefore, determining baseline immune responses to nanomaterials is of utmost importance when designing human therapeutics. We characterized the response of human immune cells to hydrogel NPs fabricated using Particle Replication in Non-wetting Templates (PRINT) technology. We found preferential NP uptake by primary CD14(+) monocytes, which was significantly reduced upon PEGylation of the NP surface. Multiplex cytokine analysis of NP treated primary human peripheral blood mononuclear cells suggests that PRINT based hydrogel NPs do not evoke significant inflammatory responses nor induce cytotoxicity or complement activation. We furthered these studies using an in vivo humanized mouse model and similarly found preferential NP uptake by human CD14(+) monocytes without systemic inflammatory cytokine responses. These studies suggest that PRINT hydrogel particles form a desirable platform for vaccine and drug delivery as they neither induce inflammation nor toxicity. From the clinical editor: The authors here fabricated hydrogel nanorods using the PRINT (Particle Replication In Nonwetting Templates) fabrication process. They tested the interaction of human immune cells with these particles and found no immunoreactivity. This finding would suggest that monodisperse PRINT particles of identical shape and size could serve a variety of clinical applications.
理想的基于纳米颗粒(NP)的药物和疫苗递送载体应无内在的细胞毒性或免疫刺激特性。因此,在设计人类治疗药物时,确定对纳米材料的基线免疫反应至关重要。我们表征了人类免疫细胞对使用非湿润模板中的颗粒复制(PRINT)技术制造的水凝胶NP的反应。我们发现原代CD14(+)单核细胞优先摄取NP,而NP表面聚乙二醇化后这种摄取显著减少。对NP处理的原代人外周血单核细胞进行的多重细胞因子分析表明,基于PRINT的水凝胶NP不会引起显著的炎症反应,也不会诱导细胞毒性或补体激活。我们使用体内人源化小鼠模型进一步开展了这些研究,同样发现人CD14(+)单核细胞优先摄取NP,且无全身性炎症细胞因子反应。这些研究表明,PRINT水凝胶颗粒形成了一个理想的疫苗和药物递送平台,因为它们既不诱导炎症也不产生毒性。临床编辑评论:作者在此使用PRINT(非湿润模板中的颗粒复制)制造工艺制造了水凝胶纳米棒。他们测试了人类免疫细胞与这些颗粒的相互作用,未发现免疫反应性。这一发现表明,形状和大小相同的单分散PRINT颗粒可用于多种临床应用。